Periocular invasive melanoma manifestation in a patient using bimatoprost: case report and literature review

Orbit. 2023 Feb;42(1):73-80. doi: 10.1080/01676830.2021.1955392. Epub 2021 Jul 28.

Abstract

Prostaglandin F2a analogs (PGAs) are considered efficacious in the first-line treatment of glaucoma. They have however been associated with a number of periocular side effects. We present a case of periocular hyperpigmentation and progression to lentigo maligna melanoma (LMM) in a patient using bimatoprost eye drops. We conducted a literature review regarding the etiology and pathophysiology of periocular pigmentation in this setting.A 71-year-old female Caucasian patient with open-angle glaucoma using bimatoprost exclusively in her right eye noticed an ipsilateral lower eyelid/upper cheek area dark lesion after commencing treatment. Examination demonstrated a heterogeneously pigmented lesion. Excisional biopsy demonstrated extensive lentigo maligna (melanoma in situ) with superficially invasive malignant melanoma in the lesion center. The patient underwent successful staged excision and reconstruction. Literature review has demonstrated case reports supporting periocular hyperpigmentation; however, there has been no description of progression to periocular lentigo maligna and melanoma in a patient using bimatoprost.

Keywords: Bimatoprost; eyelid; lentigo maligna; lentigo maligna melanoma; melanoma; prostaglandin.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Aged
  • Bimatoprost / adverse effects
  • Eyelids / pathology
  • Female
  • Glaucoma, Open-Angle* / chemically induced
  • Glaucoma, Open-Angle* / drug therapy
  • Glaucoma, Open-Angle* / surgery
  • Humans
  • Hutchinson's Melanotic Freckle* / pathology
  • Hutchinson's Melanotic Freckle* / surgery
  • Hyperpigmentation*
  • Melanoma* / drug therapy
  • Melanoma* / pathology
  • Melanoma* / surgery
  • Melanoma, Cutaneous Malignant
  • Skin Neoplasms* / pathology

Substances

  • Bimatoprost